1-3 of 3
Sharon Lea Aukerman, PhD
Close
Sort by
Journal Articles

Targeting the Wnt/β-Catenin Signaling Pathway and CD44-Mediated Adhesion As a Rational Approach to Overcome Lenalidomide Resistance in Multiple Myeloma

Chad C. Bjorklund, Ph.D., Sharon Lea Aukerman, PhD, Antonia Lopez-Girona, Ph.D., Mohamad Hussein, MD, Rajesh Chopra, PhD, Isere Kuiatse, Ph.D., Deborah J. Kuhn, Ph.D., Caimiao Wei, PhD, Robert Z. Orlowski, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 928.
https://doi.org/10.1182/blood.V118.21.928.928
Published: 2011
Journal Articles

Lenalidomide Induces Capping of CD20 and Cytoskeleton Proteins to Enhance Rituximab Immune Recognition of Malignant B-Cells

Svetlana Gaidarova, Derek Mendy, Carla Heise, PhD, Sharon Lea Aukerman, PhD, Tom Daniel, Rajesh Chopra, Antonia Lopez-Girona
Journal: Blood
Blood (2010) 116 (21): 2845.
https://doi.org/10.1182/blood.V116.21.2845.2845
Published: 2010
Journal Articles

A Non-Internalizing Anti-CD40 Antibody, CHIR-12.12, Blocks CD40L-Induced Cytokine Production and Mediates Greater ADCC Than Rituximab in Primary CLL Cells.

Xia Tong, MSc, Sharon Lea Aukerman, PhD, Karen Lin, BS, Natasha Aziz, PhD, Cheryl Goldbeck, BS, Georgios V. Georgakis, MD, Anas Younes, MD, Wen-Kai Weng, MD, PhD, Susan O’Brien, MD, William Wierda, MD, PhD, Bahija Jallal, PhD, Mohammad Luqman, PhD
Journal: Blood
Blood (2005) 106 (11): 2964.
https://doi.org/10.1182/blood.V106.11.2964.2964
Published: 2005